Sign in

ELOX on Nasdaq

Eloxx Pharmaceuticals, Inc.

American biological products company based in Bridgewater, active since 19992

In its 2026 annual report the company says: “We are a clinical-stage biopharmaceutical company developing novel, small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins. Our immediate focus is to advance the clinical development of our lead product candidate, exaluren, for the treatment of rare kidney diseases and, through our collaboration with Almirall, S.A., ZKN-013 for the treatment of rare skin diseases.”4 Its shares trade on Nasdaq under the symbol ELOX.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Fate Therapeutics, DBV Technologies or Evaxion A/S, or pick any stock.

  • TickerELOX on Nasdaq2
  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersBridgewater, United States2
  • Incorporated inDE3
  • Business addressP.O. Box 274, Arlington, Ma 024763
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300UB28QGWJMFFA112
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Corporation Service Company, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 31048092

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company developing novel, small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (“NMs”) to enable the production of full-length proteins. Targeting ribosome subunits provides a therapeutic approach to addressing a number of genetic diseases. According to the Human Gene Mutation Database, NMs account for approximately 10% to 12% of patients with a given genetic disease. There are over 7,000 inherited genetic diseases that collectively affect 350 million people worldwide. Our immediate focus is to advance the clinical development of our lead product candidate, exaluren, for the treatment of rare kidney diseases and, through our collaboration with Almirall, S.A. (“Almirall”), ZKN-013 for the treatment of rare skin diseases.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-100.0%Revenue growth, 20255

Financial statements

Revenue5$0 in 2025
0$2.0M$4.0M$6.0M$8.0M2023: $0$020232024: $6.4M$6.4M20242025: $0$02025
Operating income675-$6.4M in 2025−87% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$50.6M-$50.6M20192020: -$33.5M-$33.5M2020−34%2021: -$66.0M-$66.0M2021+97%2022: -$34.4M-$34.4M2022−48%2023: -$17.3M-$17.3M2023−50%2024: -$2.5M-$2.5M2024−86%2025: -$6.4M-$6.4M2025+161%
Net income675-$6.0M in 2025−88% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$50.9M-$50.9M20192020: -$34.6M-$34.6M2020−32%2021: -$66.7M-$66.7M2021+93%2022: -$36.1M-$36.1M2022−46%2023: -$17.1M-$17.1M2023−53%2024: -$3.1M-$3.1M2024−82%2025: -$6.0M-$6.0M2025+91%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
License and service revenue:$0$6.4M$0
Research and development$3.1M$3.6M$8.6M
General and administrative$3.4M$5.2M$8.7M
Total operating expenses$6.4M$8.8M$17.3M
Loss from operations-$6.4M-$2.5M-$17.3M
Other (income) expense, net-$443.0K$675.0K-$234.0K
Net loss-$6.0M-$3.1M-$17.1M
Net loss per share, basic-$0.49-$0.84-$6.63
Net loss per share, diluted-$0.49-$0.84-$6.63
Weighted average number of shares of common stock and pre-funded warrants used in computing net loss per share, basic12.3M shares3.8M shares2.6M shares
Weighted average number of shares of common stock and pre-funded warrants used in computing net loss per share, diluted12.3M shares3.8M shares2.6M shares

Compare Eloxx Pharmaceuticals, Inc. with another company

Corporate structure

Eloxx Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Eloxx Pharmaceuticals, Inc.

  • Eloxx Pharmaceuticals, Inc. Bridgewater, New Jersey, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Eloxx Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$05 Dec 31, 2025$05 Dec 31, 2024
Accumulated depreciation$05 Dec 31, 2025$05 Dec 31, 2024
Property and equipment, net$05 Dec 31, 2025$05 Dec 31, 2024
Operating-lease assets (leased space)$05 Dec 31, 2025$05 Dec 31, 2024

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$4.8M5 Dec 31, 2025$111.0K5 Dec 31, 2024+4210.8%

Properties, in its own words

Our principal executive offices were previously located at 480 Arsenal Way, Watertown, Massachusetts. We also previously leased office space in Ness Ziona, Israel. We are now a remotely headquartered company.

Item 2 of the 10-K filed Mar 17, 2026.4

Leadership

Who has led Eloxx Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Bruce C. Galton2006–2008
  2. Hulst Jack Van2009–2010
  3. Leslie J. Browne2010–2013
  4. Ron Martell2014
  5. Silvia Noiman2017–2018
  6. Gregory C. Williams2020–2021
  7. Sumit Aggarwal2021–now

President

  1. Bruce C. Galton2006–2008
  2. Hulst Jack Van2009–2010
  3. Leslie J. Browne2010–2014
  4. Sumit Aggarwal2021–now

Chief financial officer

  1. Joel Brooks2006–2014
  2. Daniel E. Geffken2021

Chief operating officer

  1. Gregory C. Williams2018–2020
  2. Neil S. Belloff2020–2021
2010201520202025
Board members and other officers (37)

Former names

  • Sevion Therapeutics, Inc.Oct 3, 2014 to Dec 22, 20173
  • SENESCO TECHNOLOGIES INCNov 19, 1999 to Sep 29, 20143
  • NAVA LEISURE USA INCOct 7, 1997 to May 24, 19993

Timeline

  1. Aug 11, 20268-K Results of operations54
  2. Jun 1, 20268-K Unregistered sale of shares; Change to shareholders' rights; Executive or director change55
  3. May 1, 20268-K Shareholder vote56
  4. Aug 12, 20258-K Executive or director change57
  5. Oct 17, 20248-K Executive or director change58
  6. Jul 16, 20248-K Entered a material agreement; New debt or obligation59
  7. Mar 29, 20248-K Executive or director change60
  8. Mar 14, 20248-K Entered a material agreement61
  9. Jan 9, 20248-K Entered a material agreement; Unregistered sale of shares62
  10. Dec 28, 20238-K Executive or director change63
  11. Dec 15, 20238-K Entered a material agreement; New debt or obligation64
  12. Nov 13, 20238-K Results of operations65
  13. Apr 2, 2021New chief executive Sumit Aggarwal becomes CEO12
  14. Feb 26, 2020New chief executive Gregory C. Williams becomes CEO13
  15. Dec 29, 2017New chief executive Silvia Noiman becomes CEO14
  16. Jun 26, 2014New chief executive Ron Martell becomes CEO15
  17. May 27, 2010New chief executive Leslie J. Browne becomes CEO16
  18. Nov 23, 2009New chief executive Hulst Jack Van becomes CEO17
  19. Apr 24, 2006New chief executive Bruce C. Galton becomes CEO18
  20. Sep 30, 1999Founded Eloxx Pharmaceuticals, Inc. is founded2

Calendar

Coming up

  1. Nov 10, 2026Reports results for the quarter ending Sep/202666

When it reported results

  1. Aug 11, 2026Reported quarterly or annual results54
  2. Nov 13, 2023Reported quarterly or annual results65
  3. May 16, 2023Reported quarterly or annual results67
  4. Apr 3, 2023Reported quarterly or annual results68
  5. Nov 14, 2022Reported quarterly or annual results69
  6. Aug 15, 2022Reported quarterly or annual results70
  7. May 10, 2022Reported quarterly or annual results71
  8. Apr 4, 2022Reported quarterly or annual results72

Drug trials and FDA: coming up

  1. Jun 30, 2027Phase 2 trial readout expected Phase 2 trial of Exaluren in Alport Syndrome, X-Linked: primary completion expected Jun 30, 2027 (ClinicalTrials.gov NCT07523581).73

Drug trials and FDA: recently

  1. Sep 11, 2023Phase 2 trial completed Phase 2 trial of ELX-02 in Alport Syndrome: primary completion Sep 11, 2023, results posted Feb 24, 2026 (ClinicalTrials.gov NCT05448755).74

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

155 filings to the SEC since October 2021: 3 annual reports, 9 quarterly reports, 44 major events, 48 insider forms, 16 large holders, 35 other. The latest 20:

  1. Sep 18, 2026EFFECT EDGAR
  2. Sep 11, 2026S-1 EDGAR
  3. Aug 14, 2026SCHEDULE 13G EDGAR
  4. Aug 14, 2026SCHEDULE 13G EDGAR
  5. Aug 11, 20268-K EDGAR
  6. Aug 11, 202610-Q EDGAR
  7. Jul 27, 2026SCHEDULE 13G EDGAR
  8. Jun 17, 2026SCHEDULE 13G EDGAR
  9. Jun 17, 2026SCHEDULE 13G EDGAR
  10. Jun 17, 20264 EDGAR
  11. Jun 17, 20263 EDGAR
  12. Jun 16, 2026SCHEDULE 13G EDGAR
  13. Jun 16, 2026SCHEDULE 13G EDGAR
  14. Jun 15, 2026SCHEDULE 13G EDGAR
  15. Jun 10, 20264 EDGAR
  16. Jun 10, 20264 EDGAR
  17. Jun 10, 20264 EDGAR
  18. Jun 10, 20264 EDGAR
  19. Jun 10, 20264 EDGAR
  20. Jun 9, 2026424B4 EDGAR

The 155 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 29, 2021Geffken Daniel E.INTERIM CFOBuy50,000$0.72$36.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$796.5K 2020–2020
Money received by yearMoney received by year, 2020–2020: $796.5K in all. PPP loans $796.5K.$0$200K$400K$600K$800K2020 · PPP loans: $796.5K2020
Figures by year
YearPPP loansTotal
2020$796.5K$796.5K

PPP loans

Paycheck Protection Program loans of $150,000 and up, approved April 2020 to July 2021, from the SBA86. Matched to this company by name and state.

  1. Apr 14, 2020$796.5K PPP loan (first draw) from Silicon Valley Bridge Bank NA86To ELOXX PHARMACEUTICALS, INC., Waltham MA; $807.6K forgiven Sep 7, 2021

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Nantahala Capital Management, LLC800,000$11.1M0.3%New
EcoR1 Capital, LLC400,000$5.6M0.3%New
Aberdeen Group plc400,000$5.6M0.0%New
Samsara Biocapital, LLC400,000$5.6M0.5%New
Siren, L.L.C.400,000$5.6M0.1%New
Stonepine Capital Management, LLC397,160$5.5M4.2%New
Vanguard Capital Management LLC78,680$1.1M0.0%New
Vanguard Fiduciary Trust Co10,602$147.2K0.0%New
Seven Grand Managers, LLC10,000$138.8K0.0%New
Morgan Stanley1,544$21.4K0.0%New
Vanguard Global Advisers, LLC718$10.0K0.0%New
UBS Group AG637$8.8K0.0%New
Wells Fargo & Company/mn126$1.7K0.0%New
Pioneer Family Office, LLC96$1.3K0.0%New
Royal Bank Of Canada98$1.0K0.0%New
Altshuler Shaham Ltd25$3470.0%New
Barclays PLC12$1670.0%New
Towne Trust Company, N.A5$690.0%New
Citigroup Inc4$560.0%New
Activest Wealth Management4$560.0%New
SBI Securities Co., Ltd.2$280.0%New
Point Nemo Capital, LLC1$140.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Eloxx Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAREloxx Pharmaceuticals, Inc.1
  • CIK0001035354
  • Employer ID (EIN)84-13688504
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressP.O. Box 274, Arlington, MA 024761
  • Phone781-577-53001
  • Shares outstanding4,036,459 as of Aug 7, 20268
  • Public float$330.0K as of Jun 30, 20254
  • AuditorBaker Tilly US, LLP, ewksbury, Massachusetts PCAOB ID 23; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceMar 27, 19971
  • Filings1,356 in all: 4 (513), 8-K (317), 10-Q (57), 3 (47), SC 13G/A (34), SC 13D/A (27), DEF 14A (26), 10QSB (24)1
    All 60 form types

    SC 13G (23), 10-K (19), 424B5 (17), CORRESP (16), S-8 (15), SC 13D (15), ARS (13), S-3 (12), 4/A (11), 8-K/A (11), EFFECT (11), UPLOAD (11), 10-K/A (10), SCHEDULE 13G (10), 10KSB (9), DEFA14A (9), PRE 14A (9), 424B3 (8), CT ORDER (8), NT 10-Q (8), S-1/A (8), NT 10-K (7), S-1 (5), PRER14A (4), 424B4 (3), 8-A12B (3), S-3/A (3), 10-Q/A (2), 25-NSE (2), CERT (2), D (2), DEF 14C (2), REGDEX (2), RW (2), SCHEDULE 13G/A (2), 10QSB/A (1), 10SB12G (1), 10SB12G/A (1), 5 (1), CERTAMX (1), DEFM14A (1), DRS (1), FWP (1), NT 10-K/A (1), NT 10-Q/A (1), NTN 10K (1), PRE 14C (1), PREM14A (1), REGDEX/A (1), S-1MEF (1), SC 14F1 (1), SEC STAFF ACTION (1)

  • Latest filingsAnnual report (10-K) Mar 17, 2026
    Quarterly report (10-Q) Aug 11, 2026
    Proxy statement (DEF 14A) Apr 28, 2023
    Latest 8-K (8-K) Aug 11, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.01 par valueELOXNASDAQ

From the cover page of the 10-K filed Mar 17, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Eloxx Pharmaceuticals, Inc. names in Item 1A of its 10-K filed Mar 17, 2026: 66 risks under these headings, as written.4

  • Risks Related to Our Filing History
  • We have been delinquent in our public filing obligations under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and there are no assurances that we will be successful in regaining compliance or, if regained, remaining current in our public filing obligations.
  • Our common stock is currently listed on the OTC Expert Market. The Nasdaq Stock Market LLC (“Nasdaq”) suspended trading in our common stock on the Nasdaq Capital Market as of October 16, 2023. Though we intend to seek an uplisting for our common stock to trade on the Nasdaq Capital Market, there are no assurances that we will be able to successfully uplist to the Nasdaq Capital Market or successfully maintain compliance with Nasdaq’s listing requirements.
  • Our failure to timely file periodic reports with the SEC could limit our access to the public markets to raise debt or equity capital.
  • Risks Related to Financial Position and Need for Additional Capital
  • We are a clinical stage biotechnology company and have incurred significant operating losses since our inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future. We may never achieve or maintain profitability.
  • We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our product development programs or commercialization efforts.
  • Our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern.
  • Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
  • We do not intend to pay dividends for the foreseeable future.
  • Risks Related to Drug Discovery, Development, Regulatory Approval and Commercialization
  • We are heavily dependent on the success of our lead product candidate, exaluren. If exaluren does not achieve positive results during development or suffers any material development delays, it may adversely impact the commercial viability of exaluren and our business.
The other 57 risks
  • Preclinical and clinical drug development is a lengthy and expensive process, with an uncertain outcome. Our preclinical and clinical programs may experience delays or may never advance, which would adversely affect our ability to further advance clinical development, obtain regulatory approvals or commercialize our product candidates on a timely basis or at all, which could have an adverse effect on our business.
  • We and our collaborating partners may be subject, directly or indirectly, to federal and state healthcare fraud and abuse and false claims laws and regulations. If we or our collaborating partners are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
  • Our lead product candidate, including exaluren, may cause adverse events or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance.
  • Even though we have received orphan drug designation from the FDA for exaluren for the treatment of cystic fibrosis, cystinosis, MPS I, AS, and Rett syndrome, we may not be able to maintain the benefits of orphan drug designation or obtain orphan drug marketing exclusivity for exaluren or any of our other product candidates for AS or other indications.
  • We may find it difficult to recruit and enroll patients in our clinical trials, which could cause significant delays in the completion of such trials or may cause us to abandon one or more clinical trials.
  • We may conduct clinical trials for our product candidates outside of the United States and the FDA may not accept data from such trials, in which case our development plans may be delayed, which could materially harm our business.
  • Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • The regulatory approval processes of the FDA and comparable regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.
  • Even if we obtain FDA approval for any of our product candidates in the United States, we may never obtain approval for or commercialize such candidates in any other jurisdiction, which would limit our ability to realize their full market potential.
  • If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell any of our product candidates that obtain regulatory approval, we may be unable to generate any revenue.
  • Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight.
  • There is no guarantee that we will receive in a timely fashion or at all the additional milestone or royalty payments under the Almirall License Agreement.
  • The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
  • Disruptions at the FDA and other government agencies and foreign regulatory authorities caused by funding shortages, staffing limitations, or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.
  • Developments by competitors may render our product candidates or technologies obsolete or non-competitive which would have a material adverse effect on our business, results of operations and financial condition.
  • If we are unable to develop and commercialize our product candidates, our business will be adversely affected.
  • Even if we are able to commercialize any product candidate, coverage and adequate reimbursement may not be available or such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.
  • Current and future healthcare reform and other legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain and may have a negative impact on our business and results of operations.
  • Risks Related to Our Business and Operations
  • We continue to seek opportunities to expand our business through strategic initiatives. Our efforts to identify opportunities or complete transactions that satisfy our strategic criteria may not be successful, and we may not realize the anticipated benefits of any completed acquisition, collaboration or other strategic transaction.
  • Our business could be affected by litigation, government investigations and enforcement actions.
  • We could be subject to additional tax liabilities.
  • Material weaknesses in our internal control over financial reporting could have a significant adverse effect on our business and the price of our common stock.
  • Our business could be adversely affected by the effects of widespread public health epidemics and other factors beyond our control.
  • Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.
  • Our business and operations may suffer in the event of information technology system failures, cyberattacks or deficiencies in our cybersecurity.
  • We currently rely, and plan to rely on in the future, third parties to conduct and support our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.
  • We contract with third parties for the manufacture of our product candidates for preclinical studies and our ongoing clinical trials, and expect to continue to do so for additional clinical trials and ultimately for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or be able to obtain such product candidates at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. We also rely on a single-source supplier.
  • We have vendors and third party service providers located outside of the United States that subject us to additional risks that are beyond our control and that could harm our business, financial condition, results of operations, and prospects.
  • Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel.
  • We have a limited number of employees, which could adversely affect our business and operations.
  • Our employees and independent contractors, including collaborators, principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
  • We may engage in strategic transactions that could impact our liquidity, increase our expenses, and present significant distractions to our management.
  • Risks Related to Intellectual Property
  • If we fail to adequately protect or enforce our intellectual property rights or secure rights to third party patents, the value of our intellectual property rights would diminish, and our business, competitive position and results of operations would suffer.
  • If we infringe the rights of third parties, we could be prevented from selling products, forced to pay damages and required to defend against litigation which could result in substantial costs and may have a material adverse effect on our business, results of operations and financial condition.
  • We rely on confidentiality agreements that could be breached and may be difficult to enforce which could have a material adverse effect on our business and competitive position.
  • If we cannot meet requirements under our license agreement, we could lose the rights to our product candidates, which could have a material adverse effect on our business.
  • We may become involved in lawsuits to protect or enforce or defend our intellectual property, which could be expensive, time consuming and unsuccessful and have an adverse effect on the success of our business.
  • Risks Related to Our Regional Operations
  • Potential political and economic instability in regions where we conduct business may adversely affect our results of operations.
  • We received Israeli government grants for our research and development activities and programs. The terms of such grants may require us, in the future, to pay royalties and under certain circumstances, penalties in addition to payment of royalties.
  • We may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could result in litigation and adversely affect our business.
  • Risks Related to Our Common Stock
  • Our stock price may be volatile, and purchasers of our common stock could incur substantial losses.
  • We are a smaller reporting company, and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.
  • Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.
  • Our current amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be
  • the exclusive forum for substantially all disputes between us and our stockholders and that the federal district
  • courts shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising
  • under the Securities Act, which could limit our stockholders’ ability to obtain a favorable judicial forum for
  • disputes with us or our directors, officers or employees or the underwriters or any offering giving rise to such
  • Our common stock constitutes “penny stock” within the meaning of the rules of the SEC and may be subject to greater opportunity for manipulation.
  • General Risk Factors
  • Maintaining and improving our financial controls and the requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain qualified board members.
  • Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations.
  • Future sales and issuances of our securities or rights to purchase securities, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause the prices of our securities to fall.
  • We could be subject to securities class action litigation.
  • Changing circumstances and market conditions, some of which may be beyond our control, could impair our ability to access our existing cash and cash equivalents and to timely pay key vendors and others.
  • Our insurance policies protect us from only some business risks, which will leave us exposed to significant uninsured liabilities.
  • We are subject to governmental export and import controls, economic sanctions, anti-corruption laws and regulations of the United States and other jurisdictions. We can face criminal liability and other serious consequences for violations of these laws and regulations, which could harm our business.
  • Coastlands and Domicilium own prefunded warrants to purchase a significant percentage of our capital stock and have board designation and certain consent rights, which allow them to exert meaningful influence on our company.

Legal proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business, which may include, without limitation, actions related to or based on our intellectual property and its use, customer claims, employment practices and employee complaints and other events arising out of our operations. We are currently unaware of any material pending legal proceedings to which we are party or of which our property is the subject. However, we may at times in the future become involved in litigation in the ordinary course of business. When appropriate in management’s estimation, we will record adequate reserves in our financial statements for pending litigation. Litigation is subject to inherent uncertainties, and an adverse result in any such matters could adversely impact our reputation, operations, and our financial operating results or overall financial condition. Additionally, any litigation to which we may become subject could also require significant involvement of our senior management and may divert management’s attention from our business and operations.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86